Theriva Biologics (TOVX) has released an update to notify the public and investors about a regulation fd disclosure.
Theriva Biologics, Inc. announced positive progress in their Phase 2b VIRAGE clinical trial for a new treatment combining VCN-01 with chemotherapy for metastatic pancreatic cancer. The trial, spreading across multiple sites in the U.S. and Spain, is set to proceed without modifications, as the Independent Data Monitoring Committee found no safety concerns and confirmed the treatment’s tolerability, including the feasibility of repeated doses. Enrollment for the trial is expected to be completed in the first half of 2024, marking a potential milestone in cancer therapy.
For further insights into TOVX stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
